BETHESDA, MD, November 22, 2013 — Evidera, a global leader in health economics, outcomes research, market access, data analytics and epidemiology solutions, has been awarded Best Market Access Drug Programme 2013 in the Rare & Orphan Advocacy and Research (ROAR) Awards.

The ROAR Awards were announced during the 4th Annual World Orphan Drug Congress Europe, November 14-15, 2013, in Geneva, Switzerland. The inaugural 2013 awards were created to honour and generate recognition of the efforts, accomplishments, and positive contributions of organisations and individuals in the rare disease and orphan drug industry.

“We are incredibly honored to accept this award, ” said Jon Williams, President and CEO of Evidera. “Assisting our clients in bringing new treatments to market for rare and orphan diseases is more important now than ever before. As an industry, we are getting closer to connecting the dots on multiple levels for rare and orphan diseases; science and technology are advancing at break-neck speed, patient and physician communities are becoming more connected and informed than ever before, and industry is finding new and innovative methods for helping patients obtain market access. We need to utilize this momentum and continue to innovate across multiple avenues to support advancement and access for rare disease treatments. We applaud the World Orphan Drug Congress Europe for creating a platform to discuss and share ideas in this space, and we at Evidera look forward to playing an even bigger role in the advancement of the orphan drug market in 2014.”

The Best Market Access Drug Programme Award recognizes the level of scenario planning, economic modeling, market forecasting and stakeholder mapping in a company’s market access programme, as well as its ability to leverage relationships with payers, providers and decision-makers at the global, national and local level.

About Evidera

Evidera, a wholly owned subsidiary of Symphony Technology Group, provides health economics, outcomes research, market access, data analytics and epidemiology services. We partner with life sciences organizations worldwide to optimize the market access and commercial success of their products by leveraging our unparalleled knowledge of the global payer and regulator landscape and by developing, capturing and communicating the clinical and economic evidence that our clients require to successfully market their products. Our research and consulting services are driven by world-class science and thought leadership and leverage a unique combination of capabilities.

About Symphony Technology Group

Symphony Technology Group (STG) is a strategic private equity firm with the mission of investing in and building great technology and services companies. In addition to capital, STG provides transformation expertise to enable its companies to deliver maximum value to their clients, to drive growth through innovation, to retain and attract the best talent and to achieve best in class business performance. STG’s current portfolio consists of 14 global companies. For more information, please visit

Media Contacts:

Heather Varela, Director Marketing Communications

Tom Kivett, Kivett & Company Communications